Overview

A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia

Status:
Not yet recruiting
Trial end date:
2029-01-09
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate efficacy and safety of ianalumab compared to placebo in patients with warm autoimmune hemolytic anemia, who failed at least one line of treatment.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals